159 related articles for article (PubMed ID: 25293620)
21. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of MUC1 in advanced pancreatic cancer.
Hinoda Y; Ikematsu Y; Horinochi M; Sato S; Yamamoto K; Nakano T; Fukui M; Suehiro Y; Hamanaka Y; Nishikawa Y; Kida H; Waki S; Oka M; Imai K; Yonezawa S
J Gastroenterol; 2003; 38(12):1162-6. PubMed ID: 14714254
[TBL] [Abstract][Full Text] [Related]
23. The use of radiofrequency ablation in pancreatic cancer in the midst of the dawn of immuno-oncology.
Reccia I; Kumar J; Habib N; Sodergren M
Med Oncol; 2018 Oct; 35(12):151. PubMed ID: 30284649
[TBL] [Abstract][Full Text] [Related]
24. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.
Martin RC; McFarland K; Ellis S; Velanovich V
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S443-9. PubMed ID: 23128941
[TBL] [Abstract][Full Text] [Related]
25. A Multidisciplinary Approach to Pancreas Cancer in 2016: A Review.
Fogel EL; Shahda S; Sandrasegaran K; DeWitt J; Easler JJ; Agarwal DM; Eagleson M; Zyromski NJ; House MG; Ellsworth S; El Hajj I; O'Neil BH; Nakeeb A; Sherman S
Am J Gastroenterol; 2017 Apr; 112(4):537-554. PubMed ID: 28139655
[TBL] [Abstract][Full Text] [Related]
26. Percutaneous irreversible electroporation of surgically unresectable pancreatic cancer: a case report.
Bagla S; Papadouris D
J Vasc Interv Radiol; 2012 Jan; 23(1):142-5. PubMed ID: 22221480
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
28. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
29. Cellular and molecular aspects of pancreatic cancer.
Gharibi A; Adamian Y; Kelber JA
Acta Histochem; 2016 Apr; 118(3):305-16. PubMed ID: 26868366
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
31. [Prognosis of pancreatic cancer from histopathological findings].
Nakamura Y; Inui K; Yoshino J; Okushima K; Miyoshi H
Nihon Rinsho; 2006 Jan; 64 Suppl 1():293-6. PubMed ID: 16457269
[No Abstract] [Full Text] [Related]
32. [R classification and pancreatic ductal adenocarcinoma--R 0 is R 0].
Munding J; Uhl W; Tannapfel A
Z Gastroenterol; 2011 Oct; 49(10):1423-7. PubMed ID: 21964897
[TBL] [Abstract][Full Text] [Related]
33. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery.
Martin RC; Durham AN; Besselink MG; Iannitti D; Weiss MJ; Wolfgang CL; Huang KW
J Surg Oncol; 2016 Dec; 114(7):865-871. PubMed ID: 27546233
[TBL] [Abstract][Full Text] [Related]
34. Irreversible electroporation of locally advanced pancreatic head adenocarcinoma.
Martin RC
J Gastrointest Surg; 2013 Oct; 17(10):1850-6. PubMed ID: 23929188
[TBL] [Abstract][Full Text] [Related]
35. Protein biomarker for pancreatic ductal adenocarcinoma.
Burki T
Lancet Oncol; 2017 Sep; 18(9):e511. PubMed ID: 28736187
[No Abstract] [Full Text] [Related]
36. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
37. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.
Rochefort MM; Ankeny JS; Kadera BE; Donald GW; Isacoff W; Wainberg ZA; Hines OJ; Donahue TR; Reber HA; Tomlinson JS
Ann Surg Oncol; 2013 Dec; 20(13):4322-9. PubMed ID: 23943022
[TBL] [Abstract][Full Text] [Related]
38. Challenging Topics in Pancreatic Neoplasia.
Basturk O; Krasinskas AM
Arch Pathol Lab Med; 2020 Jul; 144(7):806-807. PubMed ID: 33761530
[No Abstract] [Full Text] [Related]
39. [Clinicopathological aspects of pancreatic cancer].
Egawa S; Sunamura M; Abe H; Motoi F; Fukuyama S; Matsuno S
Gan To Kagaku Ryoho; 2005 May; 32(5):605-11. PubMed ID: 15918558
[TBL] [Abstract][Full Text] [Related]
40. Intraductal papillary mucinous neoplasms of the pancreas: clinicopathological features and long term outcome related to histopathological group.
De Moor V; Arvanitakis M; Nagy N; Coppens E; Delhaye M; Closset J
Hepatogastroenterology; 2012; 59(114):565-9. PubMed ID: 22353525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
